Key features and details
- Sensitivity: 1.6578 ng/well
- Range: 3.13 ng/ml - 200 ng/ml
- Sample type: Plasma, Serum
- Detection method: Colorimetric
- Assay type: Sandwich (quantitative)
- Reacts with: Mouse
Product nameMouse Complement C3 ELISA Kit
See all C3 kits
Intra-assay Sample n Mean SD CV% Overall < 10% Inter-assay Sample n Mean SD CV% Overall < 10%
Sample typeSerum, Plasma
Assay typeSandwich (quantitative)
Range3.13 ng/ml - 200 ng/ml
> 85 %
Sample specific recovery Sample type Average % Range Serum > 85 % - %
Assay durationMultiple steps standard assay
Species reactivityReacts with: Mouse
Predicted to work with: Rat
Mouse Complement C3 ELISA kit is a highly sensitive two-site enzyme linked immunoassay (ELISA) for measuring Complement C3 in mouse biological samples.
In this assay the Complement C3 present in samples reacts with the anti- Complement C3 antibodies which have been adsorbed to the surface of polystyrene microtitre wells. After the removal of unbound proteins by washing, anti- Complement C3 antibodies conjugated with horseradish peroxidase (HRP), are added. These enzyme-labeled antibodies form complexes with the previously bound Complement C3. Following another washing step, the enzyme bound to the immunosorbent is assayed by the addition of a chromogenic substrate, 3,3’,5,5’-tetramethylbenzidine (TMB). The quantity of bound enzyme varies directly with the concentration of Complement C3 in the sample tested; thus, the absorbance, at 450 nm, is a measure of the concentration of Complement C3 in the test sample. The quantity of Complement C3 in the test sample can be interpolated from the standard curve constructed from the standards, and corrected for sample dilution.
Storage instructionsStore at +4°C. Please refer to protocols.
Components 1 x 96 tests 100X HRP-conjugated anti-mouse Complement C3 antibody 1 x 150µl 20X Wash Buffer Concentrate 1 x 50ml 5X Diluent Concentrate 1 x 50ml Chromogen Substrate Solution 1 x 12ml Mouse Complement C3 Calibrator (lyophilized) 1 vial Mouse Complement C3 ELISA Microplate 1 unit Stop Solution 1 x 12ml
FunctionC3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates.
Derived from proteolytic degradation of complement C3, C3a anaphylatoxin is a mediator of local inflammatory process. It induces the contraction of smooth muscle, increases vascular permeability and causes histamine release from mast cells and basophilic leukocytes.
Involvement in diseaseDefects in C3 are the cause of complement component 3 deficiency (C3D) [MIM:120700]. A rare defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis.
Genetic variation in C3 is associated with susceptibility to age-related macular degeneration type 9 (ARMD9) [MIM:611378]. ARMD is a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.
Defects in C3 are a cause of susceptibility to hemolytic uremic syndrome atypical type 5 (AHUS5) [MIM:612925]. An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Note=Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype.
Sequence similaritiesContains 1 anaphylatoxin-like domain.
Contains 1 NTR domain.
modificationsC3b is rapidly split in two positions by factor I and a cofactor to form iC3b (inactivated C3b) and C3f which is released. Then iC3b is slowly cleaved (possibly by factor I) to form C3c (beta chain + alpha' chain fragment 1 + alpha' chain fragment 2), C3dg and C3f. Other proteases produce other fragments such as C3d or C3g.
Phosphorylation sites are present in the extracelllular medium.
- Information by UniProt
- Acylation stimulating protein cleavage product
Complement C3 measured in tissue extracts (total protein concentration: Ms liver - 17.46 mg/mL, Ms kidney - 15.6 mg/mL; prepared in RIPA buffer with protease inhibitor) and cell culture supernatants showing quantity (ng) per mL of tested sample. Tissue samples were diluted 100-10000 fold. Supernatants were diluted 1-10 fold.
Complement C3 measured in biological fluids of healthy species showing quantity (ng) per mL of tested sample. Samples were diluted 8000-128000 fold.
Representative standard curve using ab157711 Complement C3 Mouse ELISA kit.
ab157711 has been referenced in 17 publications.
- Park JW et al. Compensatory role of C3 convertase on the strain difference for C3 protein expression in FVB/N, C3H/HeN and C57BL/6N mice. Lab Anim Res 36:4 (2020). PubMed: 32206611
- Zha H et al. Intracellular Activation of Complement C3 Leads to PD-L1 Antibody Treatment Resistance by Modulating Tumor-Associated Macrophages. Cancer Immunol Res 7:193-207 (2019). PubMed: 30514794
- Rathore AP et al. Dengue virus-elicited tryptase induces endothelial permeability and shock. J Clin Invest 129:4180-4193 (2019). PubMed: 31265436
- Royer DJ et al. Complement and CD4+ T cells drive context-specific corneal sensory neuropathy. Elife 8:N/A (2019). PubMed: 31414985
- Zhang Z et al. Upconversion superballs for programmable photoactivation of therapeutics. Nat Commun 10:4586 (2019). PubMed: 31594932